regulated and involves numerous factors, including calcium deposition and other bone remodelling factors."

Objectives: The objective of this study was to find a signature of miR-RFs linked both to osteoporotic fracture risk and abdominal aortic calcification (AAC).

The first outcome was the link between miR-RFs levels at baseline and incident osteoporotic fractures (IOF) during 20 years; the second outcome was the link between miR-RFs levels at baseline and the increase in AAC during 17 years.

Methods: Post-menopausal women older than 50 years from the OFELY cohort (Os des Femmes de LYon) were selected if they had available serums at inclusion, and available data for each outcome.

3 miR-RFs selected after literature review because of their impact on vascular calcification and bone turnover (miR-26a-5p, 34a-5p, and 223-5p) were measured at baseline.

Bioassays of miR-RFs was conducted with miRCURY Biofluids (Exiqon) extraction kit, TaqMan Life Technologies protocol, and QuantStudio 7 flex (Applied Biosystems) for RNA quantification. Results are expressed by relative quantification of Cycle threshold (Ct).

Results: A sample of 434 age-matched women (63 [57–72] years old), 50% with incident osteoporotic fracture during the 20 years of follow-up, was included. 183 women had available data to explore AAC; 93 had an increase in Kauppi score in 17 years (58 [55–61] years old), 90 did not (55 [53–58] years old).

No significant link was underlined between miR-RFs and IOF (miR-26: 1.06 [0.85–1.27] vs. 0.99 [0.85–1.17], p=0.07; miR-34: 1.15 [0.53–1.87] vs 1.26 [0.60–2.07], p=0.35; miR-223: 1.01 [0.68–1.43] vs 1.05 [0.72–1.56], p=0.32).

No miR-RF was significantly linked to an increase in AAC (miR-26: 1.09 [0.94–1.28] vs 1.10 [0.89–1.30], p=0.95; miR-34: 0.78 [0.46–1.21] vs 0.73 [0.38–1.50], p=0.98; miR-223: 0.97 [0.69–1.22] vs 0.78 [0.56–1.22], p=0.11).

Conclusions: No association was observed between the 3 tested miR-RFs and IOF or increase in AAC. Larger studies are necessary to select interesting epigenetic pathways reproducible on wider population.

REFERENCES:

Disclosure of Interest: None declared


AB0009

GENETIC ASSOCIATION OF MITOCHONDRIAL DNA POLYMORPHISMS WITH BEHÇET’S DISEASE IN A KOREAN POPULATION


Conclusions: We performed a follow-up study to validate these possible associations between BD and 20 mtDNA alterations. m.16182A>C was associated with BD and its several clinical or laboratory characteristics a Korean population.

REFERENCES:

Acknowledgements: The current study was supported by the National Research Foundation of Korea funded by the Korean Government (grant no. NRF-2017R1C1B2008199).

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1714

AB0010

EVALUATION OF SENSITIVITY TO DNA DAMAGING AGENTS AND EFFICIENCY OF DNA REPAIR IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM PATIENTS WITH DERMATOMYOSITIS AND POLYMYSITIS

O. Brzezinska1,2, A. Macieja3, A. Lewandowska-Polak1, J. Sarkiń3, M. Kubicka1, J. Makowska1, T. Papłowski3. 1Department of Rheumatology, Immunology and Allergy, Medical University of Lodz; 2Department of Molecular Genetics, University of Lodz, Łódź, Poland; 3Department of Pathology, Ionut University, Daejeon, Korea, Republic of Ireland

Background: Idiopathic inflammatory myopathies (IBM) being one of the connective tissue diseases are a group of diseases with not fully understood pathology. The common features are production of autoantibodies, abnormal immune response against inflammatory process leading to destruction of muscle cells and internal organ involvement. Patients with inflammatory myopathies have higher risk of developing cancers. One of the processes that can

REFERENCES:
6. Łódź, Poland

Disclosure of Interest: None declared


Abstract AB0009 – Table 1

<table>
<thead>
<tr>
<th>RCRS position</th>
<th>Alteration</th>
<th>BD (n=88)</th>
<th>HC (n=116)</th>
<th>p-value</th>
<th>OR(95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>248</td>
<td>A del</td>
<td>12 (12.2%)</td>
<td>23 (17.9%)</td>
<td>1.005</td>
<td>1.499 (0.220–2.09)</td>
</tr>
<tr>
<td>304</td>
<td>C&gt;A</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>709</td>
<td>G&gt;A</td>
<td>24 (24.3%)</td>
<td>35 (27.9%)</td>
<td>0.236</td>
<td>1.492 (0.929–2.686)</td>
</tr>
<tr>
<td>3010</td>
<td>G&gt;A</td>
<td>19 (19.4%)</td>
<td>50 (25.5%)</td>
<td>0.307</td>
<td>0.702 (0.387–1.273)</td>
</tr>
<tr>
<td>3970</td>
<td>T&gt;C</td>
<td>14 (14.3%)</td>
<td>19 (9.7%)</td>
<td>0.327</td>
<td>1.553 (0.743–3.246)</td>
</tr>
<tr>
<td>4883</td>
<td>C&gt;T</td>
<td>25 (25.5%)</td>
<td>59 (30.1%)</td>
<td>0.494</td>
<td>0.795 (0.460–1.374)</td>
</tr>
<tr>
<td>5178</td>
<td>C&gt;A</td>
<td>25 (25.5%)</td>
<td>59 (30.1%)</td>
<td>0.494</td>
<td>0.795 (0.460–1.374)</td>
</tr>
<tr>
<td>6962</td>
<td>G&gt;A</td>
<td>12 (12.2%)</td>
<td>13 (6.9%)</td>
<td>0.540</td>
<td>1.380 (0.636–2.993)</td>
</tr>
<tr>
<td>10310</td>
<td>G&gt;A</td>
<td>16 (16.3%)</td>
<td>24 (12.2%)</td>
<td>0.434</td>
<td>1.398 (0.705–2.774)</td>
</tr>
<tr>
<td>10609</td>
<td>T&gt;C</td>
<td>12 (12.2%)</td>
<td>16 (8.2%)</td>
<td>0.361</td>
<td>1.570 (0.711–3.463)</td>
</tr>
<tr>
<td>12406</td>
<td>G&gt;A</td>
<td>12 (12.2%)</td>
<td>17 (8.7%)</td>
<td>0.447</td>
<td>1.469 (0.672–2.313)</td>
</tr>
<tr>
<td>12882</td>
<td>C&gt;T</td>
<td>12 (12.2%)</td>
<td>16 (8.2%)</td>
<td>0.361</td>
<td>1.570 (0.711–3.463)</td>
</tr>
<tr>
<td>13928</td>
<td>G&gt;C</td>
<td>14 (14.3%)</td>
<td>19 (9.7%)</td>
<td>0.327</td>
<td>1.553 (0.743–3.246)</td>
</tr>
<tr>
<td>14688</td>
<td>C&gt;T</td>
<td>19 (19.4%)</td>
<td>25 (25.5%)</td>
<td>0.353</td>
<td>0.722 (0.398–1.310)</td>
</tr>
<tr>
<td>16129</td>
<td>G&gt;C</td>
<td>23 (23.5%)</td>
<td>42 (21.4%)</td>
<td>0.804</td>
<td>1.124 (0.631–2.005)</td>
</tr>
<tr>
<td>16182</td>
<td>A&gt;C</td>
<td>22 (22.4%)</td>
<td>24 (12.2%)</td>
<td>0.061</td>
<td>1.026 (0.889–3.906)</td>
</tr>
<tr>
<td>16183</td>
<td>A&gt;C</td>
<td>32 (32.7%)</td>
<td>42 (21.4%)</td>
<td>0.092</td>
<td>1.766 (1.026–3.040)</td>
</tr>
<tr>
<td>16189</td>
<td>T&gt;C</td>
<td>42 (42.9%)</td>
<td>64 (32.7%)</td>
<td>0.112</td>
<td>1.547 (0.939–2.548)</td>
</tr>
<tr>
<td>16304</td>
<td>T&gt;C</td>
<td>15 (15.3%)</td>
<td>18 (9.2%)</td>
<td>0.170</td>
<td>1.787 (0.595–5.720)</td>
</tr>
</tbody>
</table>
attribute to increased risk of cancers can be genomic instability and impaired DNA repair.

**Objectives:** The aim of the study was to assess the processes of endogenous and exogenous DNA damage and its repair in patients with IIM as compared to healthy controls.

**Methods:** The study included 10 patients (9 men and 1 woman, mean age 46.6 ±16.5) with idiopathic inflammatory myopathies (dermatomyositis or polymyositis) as well as 7 healthy control individuals (4 men and 3 women, mean age 33.8±9.8). DNA damage and repair were investigated by the comet assay. To perform the comet assay human peripheral blood mononuclear cells (PBMCs) were isolated and incubated with tert-butyl hydroperoxide (t-BOOH) or bleomycin. Both compounds are common DNA damaging agents – t-BOOH induces oxidative DNA lesions whereas bleomycin induces also DNA double strand breaks (DSBs). To test the DNA repair capability, PBMCs were allowed to recover for 2 hour. The level of endogenous DNA lesions was also investigated.

**Results:** The levels of endogenous DNA damage were not statistically significantly different between tested groups (IIM-3.3±3.6% vs 3.2±3.8% in control; p=0.648). The extent of the DNA damage induced by bleomycin (IIM-23.3 ±19.5% vs 9.8±5.9%) in control as well as oxidative stress (IIM-14.7±16.2% vs 10.4±7.4% in control) was significantly higher in PBMS derived from IIM patients than in healthy counterparts (p<0.01). Kinetic curves of DNA repair are different but the background mechanism underlying observed differences in the repair curve between healthy subjects and patients need to be evaluated further.

**Conclusions:** Understanding the etiology of this phenomena in these diseases may provide insight into disease pathogenesis and explain the increased susceptibility of patients to malignancies. Finding the patients with increased DNA instability could potentially serve as a biomarker and indicate the group of patients who should be carefully screened for neoplastic disorder.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.5973

**AB0011**

**EVALUATION OF SALIVARY MiRNAs IN PATIENTS AFFECTED BY SJÖGREN’S SYNDROME AND CORRELATION WITH CLINICAL AND ULTRASONOGRAPHIC OUTCOMES**

R. Tota (!) M. Biasini(!), S. Bongiovanni, V. Mercurio(!), C. Vittori(!), L. Bocciassin, F. Rigamonti, A. Batticciotto, F. Atzeni, D. Trabattoni, P. Sarzi-Puttini.

1Rheumatology Unit, 2Biomedical and Clinical Sciences, University Hospital Luigi Sacco, Milan; 3Rheumatology Unit, AO ‘G.MARTINO’, Messina, Italy

**Background:** It has been demonstrated that miRNAs expressed in PBMCs and plasma are common DNA damaging agents

**Methods:** We collected plasmatic and salivary samples from 28 patients (27 females, mean age 64.4±10.1 years, mean disease duration 10.7±6.9 years) affected by primary SS according to ACR 2012 and/or 2016 criteria and 23 matched healthy controls. In the group of patients, the following data were recorded: ESSDAI and ESSPRI scores, anti-SSA and anti-SSB status and laboratory data, Schirmer’s test, ultrasound scores of the four major salivary glands according to Goriec et al. and concomitant treatments. The following miRNAs were extracted, retro-transcribed and quantified: miR16–5p, miR17–5p, p, miR18a-5p, miR19a-5p, miR19b–1-5p, miR20a, miR92–5p, miR146a-5p, miR146b-5p, miR181a–5p.

**Results:** The concentration of miRNAs evaluated in plasma and saliva did not significantly match both in patients and in controls, underlining a different modulation in their expression according to the corporal district. In patients and controls miRNAs 146b, 17, 18a, 18a and 146a were hyper-expressed in saliva and miRNAs 18a and 146a were hyper-expressed in saliva compared to the plasma samples. Salivary miRNAs 18a and 146a were hyper-expressed in patients and hypo-expressed in controls, when compared to plasmatic concentrations.

Comparing salivary and plasmatic patients’ miRNAs concentrations to those of healthy subjects, plasmatic miRNA16 and 18a were significantly more expressed in patients than in controls (two-tailed Wilcoxon test and Student’s t test for unpaired samples).

In SS patients, salivary miRNA 18a and 146a were significantly increased in older subjects (p=0.01 and p=0.04 respectively). Spearman’s correlation revealed that salivary miRNA146b was significantly hyper-expressed in patients with worse ESSPRI scores (p=0.02); on the contrary, salivary miRNA17, 146b and plasmatic miRNA17 were reduced in patients with higher scores at ultrasound evaluation (p=0.01; p=0.01 and p=0.04 respectively). Plasmatic concentration of miRNA18a was increased in patients with less lachrymal production at Schirmer’s test (p=0.01) and plasmatic concentration of miRNA17 was reduced in patients with higher ESR values (p=0.01). Salivary miRNA18a was significantly increased in patients with anti-La/SSb (p=0.04; Mann-Whitney U test for unpaired samples).

**Conclusions:** Our data show that the expression of salivary miRNAs 17, 18a and 146b may be altered in SS patients and associated with worse ultrasound and ESSPRI scores and anti-La/SSB positivity.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.4876

**AB0012**

**ALLELLE AND GENOTYPE FREQUENCY OF SOME GENE EXPRESSION LEVELS OF MIR-124 IN THE PLASMA OF JUVENILE IDIOPATHIC ARTHRITIS SUBTYPES**


1Institute of Genetics and Cytology of NAS of Belarus; 2Belarusian State Medical University; 34th City Children’s Clinical Hospital, Mirsk; 4Gomel Regional Children’s Clinical Hospital, Gomel; 5Grodno Regional Children’s Clinical Hospital, Grodno, Belarus

**Background:** In spite of the fact that chronic arthritis has been the core of paediatric rheumatology, etiology and pathogenesis of juvenile idiopathic arthritis (JIA) are still unclear. It is important to ascertain genetic nature of such a heterogeneous disease.

**Objectives:** The aim of the study was to assess the role of some SNPs of six genes implicated in immune and inflammatory responses: TNF(-rs1800629, rs3161525), PTPN22 (rs2476601), MIF (rs755622, rs5844572), TRAF5 (rs3761847), CTLA4 (rs5742909, rs231775), STAT4 (rs7574868); as well as homozygous deletions of xenobiotic transformation genes GSTT1 and GSTM1.

**Methods:** 206 patients diagnosed with JIA (mean age 8.87±4.92), and 218 hospital controls with no signs of autoimmune or inflammatory diseases (mean age 13.8±5.7±2.72) were recruited for the study. The JIA patients were divided into subgroups according to ITAR classification criteria; the majority of them (125 patients) had oligoarthritis, 42 children developed RF-negative polyarthritis and 27 patients were diagnosed with systemic arthritis. Genomic DNA was extracted from peripheral blood samples and analyzed by means of the phenol-chloroform method. SNPs were genotyped using PCR-FLP, Real-Time PCR or fragmental analysis.

**Results:** The allele frequencies for all SNPs in the hospital control group were similar to those in European populations. The allele and genotype frequency distribution for all SNPs was identical in patients and controls. However, when comparing distinct subtypes of JIA, STAT4 polymorphism demonstrated higher frequencies of minor T allele (30.5% vs. 17.8%, p=0.01, OR=2.03, 95% CI [1.14–3.6]) and G/T genotype (46.3% vs. 25.6%, p=0.03, OR=2.51, 95% CI [1.2–5.24]) in RF-negative polyarthritis than in oligoarthritis. On the contrary, AGSTT1 appeared to prevail in oligoarthritis (23.7% vs. 7.9% in RF-negative polyarthritis, p=0.03, OR=3.6, 95% CI [1.03–12.7]). As to systemic arthritis, it was shown, that minor G allele of TRAF5 was more frequent in comparison with oligoarthritis (p=0.037, OR=2.43, 95% CI [1.05–5.6]).

**Conclusions:** The results obtained can be considered as evidence for distinct genetic nature of the different JIA subtypes.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2018-eular.5087

**AB0013**

**EXPRESSION LEVELS OF MIR-124 IN THE PLASMA OF RHEUMATOID ARTHRITIS PATIENTS**

R. Shumnaliev(), D, Chakabava(), V. Shoumrailova–Ivanova, P. Mitivoa, R. Kaneva(), Z. Kolarov(), S. Mirov(). 1Department of Internal Medicine, Clinic of Rheumatology, “Molecular Medicine Center, Department of Medical Chemistry and Biotechnology, Medical University – Sofia, 2University Hospital “Alexandrovska”, Medical University – Sofia, Bulgaria, 3University Hospital “Prof. Ivan Mitev”, Medical University – Sofia, Bulgaria, Bulgaria, Bulgaria

**Background:** Micro-rnucleic acids (microRNAs) comprise a class of small non-coding RNAs that regulate gene expression on post transcriptional level. Levels of miR-124 have been found to be decreased in rheumatoid arthritis (RA) synovocytes and in vivo studies have shown that treatment with pre-miR-124 suppresses the progression of joint damage1.

**Objectives:** To evaluate the expression levels of miR-124–3p in plasma of RA patients and to determine its possible role as biomarker for diagnosis and disease monitoring.

**Methods:** 34 RA patients according to the 1987 ACR criteria were included in the study. Expression levels of miR-124–3p in the plasma were determined by PCR